4784-02-5

Basic information

• Product Name: 2,3-DIHYDROXY-6,7-DIMETHOXYQUINOXALINE
• Synonyms: 2,3-DIHYDROXY-6,7-DIMETHOXYQUINOXALINE;6,7-Dimethoxy-1,4-dihydro-2,3-quinoxalinedione monohydrate, 98%;6,7-diMethoxyquinoxaline-2,3-diol;6,7-Dimethoxyquinoxaline-2,3(1H,4H)-dione
• CAS NO: 4784-02-5
• Molecular Formula: C10H10N2O4
• Molecular Weight: 222.2
• EINECS: -0
• Mol File: 4784-02-5.mol
• Article Data: 4

Chemical Properties

• Melting Point: 350-354°C
• Boiling Point: 499.3 °C at 760 mmHg
• Flash Point: 255.8 °C
• Appearance: /
• Density: 1.312 g/cm³
• Vapor Pressure: 1.36E-10mmHg at 25°C
• Refractive Index: 1.552
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2,3-DIHYDROXY-6,7-DIMETHOXYQUINOXALINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIHYDROXY-6,7-DIMETHOXYQUINOXALINE(4784-02-5)
• EPA Substance Registry System: 2,3-DIHYDROXY-6,7-DIMETHOXYQUINOXALINE(4784-02-5)

Safety Data

• Hazardous Substances Data: 4784-02-5(Hazardous Substances Data)

Usage

General Description

The chemical 2,3-Dihydroxy-6,7-dimethoxyquinoxaline is a compound with a quinoxaline structure. It is classified as a heterocyclic compound, containing two oxygen atoms and two methoxy groups attached to the quinoxaline ring. This chemical has been studied for its potential biological and pharmacological activities, particularly its antioxidant properties and potential use in medicinal chemistry. Its structure and properties make it a valuable compound for further research in the fields of pharmacology and drug development.

InChI:InChI=1/C10H10N2O4/c1-15-7-3-5-6(4-8(7)16-2)12-10(14)9(13)11-5/h3-4H,1-2H3,(H,11,13)(H,12,14)

Upstream product

• 144-62-7 oxalic acid 
• 27841-33-4 4,5-dimethoxybenzene-1,2-diamine 
• 91-16-7 1,2-dimethoxybenzene 
• 3395-03-7 4,5-dimethoxy-1,2-dinitrobenzene 
• 6153-56-6 oxalic acid dihydrate 

Downstream Products

• 1790-91-6 2,3-Dichloro-6,7-dimethoxyquinoxaline 

Relevant articles and documents

PHOSPHOGLYCERATE KINASE INHIBITORS

Disclosed are compounds of formula (I) or pharmaceutical acceptable salts thereof, wherein R1, R2, R3 and R4 are as defined in the description. Disclosed are also the methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as phosphoglycerate kinase.

Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.